These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30064826)

  • 1. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
    Bhat M; Mara K; Dierkhising R; Watt KDS
    Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
    Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
    Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.
    Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S
    PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L
    World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
    Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
    Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Trends of De Novo Malignancy Development After Heart Transplantation.
    Youn JC; Stehlik J; Wilk AR; Cherikh W; Kim IC; Park GH; Lund LH; Eisen HJ; Kim DY; Lee SK; Choi SW; Han S; Ryu KH; Kang SM; Kobashigawa JA
    J Am Coll Cardiol; 2018 Jan; 71(1):40-49. PubMed ID: 29301626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National survey of de novo malignancy after solid organ transplantation in Japan.
    Miyazaki T; Sato S; Kondo T; Kusaka M; Gotoh M; Saiki Y; Ono M; Kokudo N; Enosawa S; Satoh S; Soeda E; Furukawa H; Kobayashi E; Nagayasu T
    Surg Today; 2018 Jun; 48(6):618-624. PubMed ID: 29380136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients.
    Tsai YF; Chen HP; Liu FC; Liu SH; Chen CY; Cheng CW; Lin JR
    Oncotarget; 2016 Dec; 7(50):83784-83794. PubMed ID: 27626495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.
    Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC
    Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.
    Gao Y; Twigg AR; Hirose R; Roll GR; Nowacki AS; Maytin EV; Vidimos AT; Rajalingam R; Arron ST
    JAMA Dermatol; 2019 Mar; 155(3):307-314. PubMed ID: 30673077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo malignancy in heart transplant recipients: A single center experience in Japan.
    Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
    J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
    Opelz G; Unterrainer C; Süsal C; Döhler B
    Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo malignancies after intestinal and multivisceral transplantation.
    Abu-Elmagd KM; Zak M; Stamos JM; Bond GJ; Jain A; Youk AO; Ezzelarab M; Costa G; Wu T; Nalesnik MA; Mazariegos GV; Sindhi RK; Marcos A; Demetris AJ; Fung JJ; Reyes JD
    Transplantation; 2004 Jun; 77(11):1719-25. PubMed ID: 15201672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
    Gutierrez-Dalmau A; Campistol JM
    Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.
    Rademacher S; Seehofer D; Eurich D; Schoening W; Neuhaus R; Oellinger R; Denecke T; Pascher A; Schott E; Sinn M; Neuhaus P; Pratschke J
    Liver Transpl; 2017 Nov; 23(11):1404-1414. PubMed ID: 28590598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
    Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
    Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation".
    Wareham NE; Li Q; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Perch M; Rasmussen A; Sørensen SS; Mocroft A; Lundgren JD
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3125-3135. PubMed ID: 31587105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
    Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
    Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of cancer risk among US solid organ transplant recipients.
    Engels EA; Pfeiffer RM; Fraumeni JF; Kasiske BL; Israni AK; Snyder JJ; Wolfe RA; Goodrich NP; Bayakly AR; Clarke CA; Copeland G; Finch JL; Fleissner ML; Goodman MT; Kahn A; Koch L; Lynch CF; Madeleine MM; Pawlish K; Rao C; Williams MA; Castenson D; Curry M; Parsons R; Fant G; Lin M
    JAMA; 2011 Nov; 306(17):1891-901. PubMed ID: 22045767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
    Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
    Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.